Aldesleukin - ILTOO Pharma

Drug Profile

Aldesleukin - ILTOO Pharma

Alternative Names: ILT-101; Low dose il2 - ILTOO Pharma; Low dose rhIL2 - ILTOO Pharma; Low-dose interleukin-2 - ILTOO Pharma

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer Assistance Publique Hopitaux de Paris; ILTOO Pharma
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Phase I Multiple sclerosis

Most Recent Events

  • 31 May 2017 Servier signs a license option agreement with ILTOO Pharma to develop and commercialise aldesleukin for Systemic lupus erythematosus worldwide (except USA and Japan)
  • 01 Nov 2016 Phase-II clinical trials in Systemic lupus erythematosus in Austria, Bulgaria, France, Germany, Mauritius, Portugal, Romania, Spain (SC) (NCT02955615)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top